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Background and purpose: In thoracic irradiation, the maximum radiation dose is restricted by the risk of
radiation-induced cardiopulmonary damage and dysfunction limiting tumor control. We showed that
radiation-induced sub-clinical cardiac damage and lung damage in rats mutually interact and that com-
bined irradiation intensiﬁes cardiopulmonary toxicity. Unfortunately, current clinical practice does not
include preventative measures to attenuate radiation-induced lung or cardiac toxicity. Here, we investi-
gate the effects of the ACE inhibitor captopril on radiation-induced cardiopulmonary damage.
Material and methods: After local irradiation of rat heart and/or lungs captopril was administered orally.
Cardiopulmonary performance was assessed using biweekly breathing rate measurements. At 8 weeks
post-irradiation, cardiac hemodynamics were measured, CT scans and histopathology were analyzed.
Results: Captopril signiﬁcantly improved breathing rate and cardiopulmonary density/structure, but only
when the heart was included in the radiation ﬁeld. Consistently, captopril reduced radiation-induced
pleural and pericardial effusion and cardiac ﬁbrosis, resulting in an improved left ventricular end-
diastolic pressure only in the heart-irradiated groups.
Conclusion: Captopril improves cardiopulmonary morphology and function by reducing acute cardiac
damage, a risk factor in the development of radiation-induced cardiopulmonary toxicity. ACE inhibition
should be evaluated as a strategy to reduce cardiopulmonary complications induced by radiotherapy to
the thoracic area.
 2014 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 114 (2015) 96–103Thoracic tumors are among the most common human
malignancies [1]. The treatment of choice often includes radiation
therapy. Unfortunately, the radiation dose that can be safely
administered to the tumor is limited by the risk of radiation-
induced toxicity of the surrounding tissues.
The radiation dose emitted to the heart following radiotherapy
is of particular concern [2,3]. Speciﬁcally, the prevalence of late
onset heart failure has been reported including accelerated athero-
sclerosis, pericardial and myocardial ﬁbrosis, conduction abnor-
malities, and injury to cardiac valves [4,5]. Both incidence and
severity of radiation-induced heart toxicity (RIHT) increase with
higher radiation doses, larger volumes exposed, a younger age at
time of exposure, and greater time elapse following treatment
[6]. In addition, the absolute radiation-related risk for a majorcardiac event is far greater with pre-existing cardiac risk factors
or ischemic cardiac disease in women treated for breast cancer.
Unfortunately, even with the most advanced photon techniques
most women still receive doses of greater than 1–5 Gy to the
heart [3].
Interestingly, the risk of radiation-induced lung toxicity (RILT),
another potentially life-threatening side effect of radiotherapy of
thoracic tumors [7], is enhanced when pre-existing cardiac disease
exists [8] and the heart is co-irradiated [9–13]. RILT traditionally is
divided into an early inﬂammatory phase, termed ‘‘radiation pneu-
monitis’’, and a late ﬁbro productive phase, termed ‘‘ﬁbrosis’’.
Recently, in a preclinical model, we found that, in concert with
inﬂammation, radiation-induced vascular remodeling played a
major role in the etiology of early RILT [14]. It was shown that lung
irradiation induced early pulmonary vascular remodeling which
resulted in pulmonary hypertension and right ventricle (RV)
hypertrophy which eventually lead to cardiopulmonary dysfunc-
tion. Additionally, heart irradiation may cause an increased left
ventricular (LV) end-diastolic pressure, perivascular ﬁbrosis and
consequential pulmonary edema [15]. Although RIHT is regarded
as a late side effect of radiotherapy, these recent preclinical
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function early after irradiation, albeit without apparent clinical
symptoms. As such, both lung and heart irradiation can cause pul-
monary and cardiac toxicity through different mechanisms which
consequentially lead to an intensiﬁed loss of cardiopulmonary per-
formance after combined irradiation [15]. Our experimental set-up
presented herein allows for accurate proton irradiation of speciﬁc
lung sub-volumes and the heart, and provides a model where early,
previously unnoticed subclinical cardiac damage can be visualized.
Using the interaction between lung and cardiac damage, we are
able to study the physiological mechanism and potential mitiga-
tion of early subclinical cardiac damage that is potentially respon-
sible for the development of late symptomatic damage.
Inhibition of the renin-angiotensin system (RAS) seems to be an
alluring strategy for attenuating radiation-induced cardiopulmo-
nary dysfunction. There is overwhelming evidence implicating
ACE inhibitors in the protection from adverse cardiac remodeling
and heart failure development [17]. Moreover, it is known that
RAS plays a role in cardiac remodeling and interstitial ﬁbrosis
[18]. Interestingly, preclinical studies indicate that suppression of
the RAS may ameliorate radiation-induced toxicity in different
organs like the kidneys [19], the central nervous system [20] and
lungs [21,22]. However, in the latter study interaction with cardiac
damage after whole thorax irradiation was not assessed. Therefore,
in the current study we aim to investigate the effect of ACE inhibi-
tion on early radiation-induced heart damage.Materials and methods
See Supplementary data for complete materials and methods.Animals
The animals used in the experiments were adult male albino
Wistar rats of the Hsd/Cpb:WU strain. The experiments were
performed in agreement with the Netherlands Experiments on
Animals Act (1977) and the European Convention for the Protec-
tion of Vertebrate Animals Used for Experimental Purposes
(Strasbourg, 18.III.1986).Local lung and heart irradiation
To induce cardiopulmonary damage, rat hearts, lungs, or both
were irradiated to 20 Gy (single fraction) using the shoot-through
technique with 150 MeV protons from the cyclotron at the
Kernfysisch Versneller Instituut, as published previously
[9,11,23,24]. Rats were given captopril in the drinking water with
a daily dose of 30–60 mg/kg body mass, comparable with that
given clinically. The animals (sham) treated with captopril were
observed for 3 months after irradiation to determine cardiopulmo-
nary function, structure and molecular changes as described
below.Breathing rate assay
To assess response of cardiopulmonary function to radiation,
breathing rate (BR) was measured before and every two weeks
after the irradiations up to week 12, as previously described
[10,23].CT imaging
Local density changes were assessed using CT imaging 8 weeks
after irradiation. The CT images were analyzed with our recently
developed highly-sensitive CT analysis method [25].Cardiac hemodynamic measurements
To investigate the cardiac physiological changes early after
heart and/or lung irradiation, LV or RV hemodynamic measure-
ments were carried out 8 weeks after irradiation. For LV measure-
ments the recorded parameters included LV end-diastolic and
end-systolic pressure (LVEDP and LVESP), dp/dtmax (maximum
rate of LV pressure change), dp/dtmin (minimum rate of LV
pressure change) and Tau (LV relaxation constant). For RV hemo-
dynamic measurement the right ventricle pressure (RVP) and
pulmonary artery pressure (PAP) were recorded.Histopathology
Sections of the rat lungs, LV, RV and intraventricular septum
(IVS) were stained with Hematoxylin & Eosin (HE) and Masson’s
Trichrome (MT) and analyzed morphologically for signs of paren-
chymal and vascular damage or cardiac damage, respectively.Quantitative polymerase chain reaction (QPCR)
Total RNA was extracted from the heart LVs and mRNA levels of
ANP and BNP were measured by QPCR.Statistical analysis
Data are expressed as mean values (means ± SEM). Statistical
analyses were performed using the two-way repeated measures
ANOVA followed by the post hoc Tukey or Bonferroni correction
for multiple comparisons and the log-rank (Mantel–Cox) to com-
pare distributions of two groups. Correlational analyses were per-
formed using the Pearson correlation coefﬁcient. In all statistical
analyses, signiﬁcance was deﬁned as P < 0.05.
Results
Captopril decreases structural and functional damage in irradiated
hearts
To study the inﬂuence of ACE inhibition on early radiation-
induced cardiac damage, we ﬁrst investigated the effect of capto-
pril on cardiac structure and function. Rat hearts were irradiated
(HIR) (Supplementary Fig. S1A), thereafter captopril was adminis-
tered. We assessed the effect of captopril on irradiation-induced
LV perivascular and interstitial ﬁbrosis [15]. Eight weeks after irra-
diation, perivascular ﬁbrosis developed in the LV, but this was sig-
niﬁcantly decreased with captopril treatment (Fig. 1A and B).
Moreover, captopril decreased the LV interstitial ﬁbrosis score in
HIR as well as in un-irradiated animals (Fig. 1C and D). Perivascu-
lar/interstitial ﬁbrosis is known to be an important factor in the
pathophysiological process contributing to diastolic dysfunction
by impairing cardiac relaxation [15,17,26]. Therefore, we next
investigated whether the observed decrease in LV perivascular
and interstitial ﬁbrosis by captopril treatment translated into an
improved cardiac diastolic function. Indeed, HIR was associated
with increased LVEDP and the LV relaxation constant, Tau, which
were both normalized by captopril treatment (Fig. 1E and F). These
effects are independent of any changes in systemic blood pressure,
maximum and minimum rates of LV pressure change (dPdtmax
and dPdtmin) or changes in LV weight, since these parameters
were comparable between captopril and control-treated rats (Sup-
plementary Fig. S2). The secretion of brain natriuretic peptide
(BNP) and atrial natriuretic peptide (ANP) are stimulated by exces-
sive myocardial stretch [27]. Therefore we assessed BNP and ANP
mRNA levels in the irradiated LV by qPCR. HIR lead to increased
ANP and BNP mRNA, which appeared to be lowered by captopril
treatment, albeit not signiﬁcantly (Supplementary Fig. S3A and B).
Fig. 1. Captopril decreases structural and functional damage in irradiated hearts. (A and B) Immunohistochemical staining and morphological quantiﬁcation of perivascular
ﬁbrosis and interstitial ﬁbrosis (C and D) in irradiated hearts shows a signiﬁcant reduction after captopril treatment. Masson trichrome staining was performed: red
stain = muscle ﬁber, blue stain = collagen. Scale bar: 100 lm. Data are presented as means ± SEM; nP 3. (E) Heart irradiation induces LV diastolic dysfunction. This was
shown by increased left ventricle end-diastolic pressures (LVEDP). Captopril treatment decreased the elevated pressures after HIR. Data are presented as means ± SEM; nP 4.
(F) HIR leads to an increased LV relaxation constant Tau. Treatment with captopril leads to a signiﬁcant decrease of Tau after HIR. Data are presented as mean ± SEM; nP 4.
(G) Early cardiopulmonary dysfunction was assessed by increase in breathing rate (BR). LIR induces increased BR; captopril treatment did not affect BR. LHIR enhanced BR
increase compared to LIR, and captopril attenuated early radiation-induced cardiopulmonary dysfunction in LHIR. Data are presented as mean area under BR increase curve
from week 0 to 8 after irradiation: means ± SEM; n = 9. ⁄⁄⁄P < .001, ⁄⁄P < .01 compared with control. ###P < .001, ##P < .01, #P < .05 comparison between ±captopril treatment.
(For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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dysfunction only when the heart is co-irradiated
Since captopril signiﬁcantly protects against radiation-induced
structural and functional cardiac changes, we hypothesized that
it should also exert protective effects on the lung [15,28]. There-
fore, we next investigated the effect of captopril on cardiopulmo-
nary dysfunction early after irradiation using our non-invasive
heart and lung interaction rat model.
We measured BR as a measure of cardiopulmonary function in
rats irradiated on the heart, lung, both heart and lung, and treated
the animalswith captopril including a sham-treated group (see Sup-
plementary Fig. S4). Captopril treatment followingadministrationof
50%20 Gy lung irradiation (LIR) (Supplementary Fig. S1C) resulted in
a BR increase of 40 breaths per minute (bpm) at 6–8 weeks post-
irradiation that was similar to the sham-treated animals (Supple-
mentary Fig. S5) and as previously described [10]. Indeed, analysis
of the area under the curve of the BR increase fromweek 0 to 8 after
irradiation indicated (Fig. 1G) that captopril did not inﬂuence the
control and radiation-induced BR increase after LIR.
Next, we investigated the effect of ACE inhibition on BR after
cardiac irradiation. As observed in our previous experiments, HIR
does not signiﬁcantly affect the BR nor does HIR with captopril
treatment (Fig. 1G and Supplementary Fig. S5B). However, after
combined heart and 50% lung irradiation (LHIR) (see Supplemen-
tary Fig. S1B), captopril signiﬁcantly reduced the enhanced BR
observed after untreated LHIR (Fig. 1G and Supplementary
Fig. S5B). As such, the enhanced cardiopulmonary dysfunction after
inclusion of the heart in the irradiation ﬁeld was completely
diminished after captopril treatment leading to a BR level compa-
rable to the LIR animals. In summary, captopril only ameliorates
radiation-induced BR increase when the heart is co-irradiated.
Captopril treatment reduces lung damage measured by CT after
(co-)irradiation of the heart
Thoracic irradiation leads to structural changes of heart and
lungs. Therefore, we assessed the effect of captopril on these struc-
tural changes by using our recently developed CT analysis method
[25] which is highly sensitive for non-invasive assessment of tho-
racic structural changes.
Consistent with the improved cardiopulmonary function, the
severe structural changes of the heart and lungs observed afterFig. 2. Captopril treatment improves cardiopulmonary structure after HIR and/or LHIR de
that LHIR leads to structural changes in the thorax which improves signiﬁcantly with ca
presented with pleural ﬂuid in their thoracic cavity, whereas in the captopril-treated gr
(89%) and pericardial effusion (67%), while in captopril-treated animals this was redu
compared with control. #P < .05, ##P < .01 comparison between ±captopril treatment.LHIR were signiﬁcantly reduced after captopril treatment (Fig. 2A
and B), and again, this was only observed when the heart was
co-irradiated. These structural changes are due to, for example,
pleural or cardiac effusion, pulmonary edema, inﬁltration or ﬁbro-
sis. Therefore, to further investigate how captopril improves car-
diopulmonary function and structure, we visually assessed the
presence or absence of effusion. After opening the thorax and dia-
phragm of the animals, no animals from the LIR group but most of
the HIR and LHIR animals presented with effusion in their pleural
cavity. Moreover, none of the HIR animals treated with captopril
showed signs of pleural effusion. A similar observation was made
for pleural effusion after LHIR and captopril treatment (Fig. 2C).
Several animals also presented with pericardial effusion in combi-
nation with pleural effusion. LHIR led to pericardial effusion in 6
out of 9 irradiated animals. After captopril treatment, only 1 out
of 9 animals presented with pericardial effusion (Fig. 2C). Pleural
and pericardial effusion, known side effects of thoracic irradiation
[7,29], were clearly diminished by ACE inhibition.Captopril treatment decreases RILT only when the heart is
(co-)irradiated
We already showed that early radiation-induced damage to car-
diac structures is reduced with captopril treatment which may
indirectly lead to less pleural effusion. To study this in more detail
we next analyzed lung morphology. Morphologic analysis showed
that captopril treatment lead to signiﬁcantly less alveolar inﬂam-
mation, inﬁltrates and early ﬁbrosis after HIR (Fig. 3A, B and D).
After LHIR, captopril treatment signiﬁcantly reduced inﬂammation,
inﬁltrates and interstitial edema in the lungs (Fig. 3A, B and C).
These features may explain the decrease of pleural effusion
following captopril treatment. Taken together, captopril treatment
decreases RILT, but consistent with the previous ﬁndings, this
effect is observed only when the heart is (co-)irradiated.
ACE inhibition does not protect the pulmonary vasculature after
thoracic irradiation
Previously, we found that radiation-induced pulmonary
vascular remodeling is an important factor in the development of
RILT resulting in pulmonary hypertension and RV hypertrophy
that eventually leads to cardiopulmonary dysfunction [14,15]. Intected by CT imaging. CT imaging (A) and CT analysis with the DS method (B) show
ptopril treatment. (C) At the peak of early RILT, 8 weeks PI, 7 out of 9 HIR animals
oup, none of the animals had pleural ﬂuid. Animals with LHIR had pleural effusion
ced to 56% and 11%, respectively. DS data are presented ±SEM; nP 3; ⁄⁄⁄P < .001
Fig. 3. Lung morphology after LIR, HIR and LHIR with or without captopril treatment. (A) LIR, HIR and LHIR all lead to a signiﬁcant increase in alveolar inﬂammation. Captopril
signiﬁcantly reduced inﬂammation after HIR and LHIR. (B) LIR, HIR and LHIR lead to increased alveolar inﬁltrates. Captopril treatment signiﬁcantly decreased inﬁltration after
HIR. (C) HIR and LHIR lead to interstitial edema. Captopril treatment signiﬁcantly decreased interstitial edema. (D) Early pulmonary ﬁbrosis presented after HIR and LHIR,
which was signiﬁcantly reduced by captopril. Data are presented as means ± SEM; nP 4; ⁄⁄⁄P < .001, ⁄⁄P < .01, ⁄P < .05 compared with control. ###P < .001, ##P < .01, #P < .05
comparison between ± captopril treatment.
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damage which also inﬂuenced cardiopulmonary function. To this
end, we studied the effect of captopril on early radiation-induced
pulmonary vascular damage. We analyzed pulmonary vascular
remodeling/occlusion, pulmonary artery pressure (PAP) and RV
hypertrophy in the non- and captopril-treated animals. Consistent
with our previous experiments, LIR, HIR and LHIR lead to vascular
remodeling/occlusion in- and out-of the irradiated ﬁeld indicating
a global vascular response in the lungs, while HIR caused vascular
remodeling only in the irradiated ﬁeld (Fig. 4A and B). Captopril
treatment did not decrease vascular remodeling. Consistent with
this, no differences in PAP or RV hypertrophy were observed
(Fig. 4C and D, Supplementary Fig. S6). It therefore appears that
although captopril ameliorates cardiopulmonary dysfunction after
combined heart and lung irradiation, this cannot be explained by a
protective effect on the pulmonary vasculature which is equally
damaged in animals with or without captopril.
In summary, these data indicate that captopril solely protects
the heart from radiation damage. Captopril treatment attenuated
radiation-induced pleural and pericardial and cardiac ﬁbrosis
resulting in an improved LVEDP and Tau. In addition, captopril
reduced RILT, but only when the heart was co-irradiated.
Discussion
In the current study we show that ACE inhibition attenuated
early radiation-induced heart damage and consequentially pre-
vented the inﬂuence of dose to the heart on lung toxicity.Speciﬁcally, we show that captopril prevented LV perivascular
ﬁbrosis and the elevations in LVEDP induced by heart irradiation,
thus, preventing LV diastolic dysfunction and consequent pulmon-
ary damage. RIHT after cancer therapy is generally believed to be a
late side effect. However, evidence from our studies [15] as well as
other preclinical [30,31] and clinical [32,33] studies suggest that
radiation may already exert an early effect on the heart. Although
this early effect is subtle and subclinical, it may have detrimental
consequences when combined with lung irradiation. Apart from
this, it may exert late effects, such as ischemic heart disease/accel-
erated atherosclerosis, pericardial and myocardial ﬁbrosis, conduc-
tion abnormalities, and injury to cardiac valves [4,5]. In our
experimental model, captopril reduced the heart component of
thoracic irradiation-induced damage, diminishing its effect on total
early cardiopulmonary damage which only became clinically dis-
cernible when both heart and lung were irradiated.
The ACE inhibitor, captopril, was selected based on previous
radiation studies where it was proven to be the most success-
ful thus far in reducing radiation damage to multiple organs
[20,34–36].
However, an attenuating effect on the hearts function after irra-
diation its affect on the heart has not been reported. This is inter-
esting because many studies have shown that cardiac dysfunction
other than caused by radiation can be attenuated by ACE
inhibition.
Previous studies showed that ACE inhibition has a protective
effect on the lung [21,22,34,37] after thoracic irradiation. However,
in these studies the heart was always co-irradiated. In the current
Fig. 4. ACE inhibition does not protect the pulmonary vasculature after thoracic irradiation. (A) Vascular remodeling is present in- and out- of the irradiated ﬁeld after LIR,
HIR and LHIR with or without captopril treatment. (B) Quantiﬁcation shows a signiﬁcant increase of luminal occlusion in the irradiated ﬁelds of all the groups. Captopril
treatment does not change the level of luminal occlusion. The outcome from each group was subtracted from the control group and then presented in the graphs. (C) Captopril
does not prevent the development of right ventricle (RV) hypertrophy. The increased workload of the RV leads to right ventricle hypertrophy (RVH) after LIR and LHIR.
Captopril showed no effect on the development of RVH in these groups. (D) Captopril had no effect on pulmonary artery pressure after LIR and LHIR. LIR and LHIR lead to an
elevated pulmonary artery pressure; no effect of captopril was observed. Data are presented as means ± SEM; nP 4; ⁄⁄⁄P < .001, ⁄⁄P < .01, ⁄P < .05 compared with control.
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enabled selective irradiation of only the lungs, or virtually only the
heart. This helped to elucidate that ACE inhibition does not reduce
RILT directly, but rather indirectly by reducing acute heart damage
which lead to secondary reductions in pulmonary function loss,
inﬂammation, edema and ﬁbrosis. Apart from their hypotensive
action, ACE inhibitors are known to have other properties such as
anti-inﬂammatory action [38]. Further, it has been suggested that
the sulfhydryl group in the molecular structure of captopril confers
in a free radical scavenger activity, and this can account in part for
its radioprotection [39]. It might act as an antioxidant to reduce
inﬂammatory reactive oxygen species and thus mitigate radiation-
induced toxicity. In this study it was found that captopril reducedﬁbrosis in rat hearts early after irradiation, which in the ﬁeld of car-
diology research is a known property of captopril [40,41].
Reduction of early radiation-induced cardiac ﬁbrosis and conse-
quently cardiac diastolic dysfunction may be of importance for the
development of late cardiac damage. Interestingly, radiation-
induced myocardial ﬁbrosis that occurs much later can be reduced
by captopril [42]. Given that in our model we found ACE inhibition
to improve not only cardiac structure, but also function early after
irradiation, implicates an important therapeutic application of ACE
inhibitors in the ﬁeld of thoracic radiation oncology that warrants
further investigation.
Although many differences exist between our animal studies
and radiotherapy in the clinic, for example, single dose versus
102 Captopril reduces acute cardiac damagefractionation, the presence of patient related co-morbidities,
patient pulmonary/cardiac status, and concomitant chemotherapy,
there are indications that the same mechanisms might play a role
in humans. Both preclinical and clinical studies showed that Ag II
may initiate cardiac perivascular ﬁbrosis and diastolic dysfunction
[43,44]. Therefore, reduction of ﬁbrosis by ACE inhibition in rats
may show reduction in the human heart as well. Moreover, treat-
ment with ACE inhibitors during thoracic irradiation has already
shown positive effects, albeit without underpinning the mecha-
nism. Acute respiratory complications and post-radiotherapy
radiological changes such as lung consolidation were less likely
to develop in lung cancer patients who were treated with ACE
inhibitors [37,45]. As in preclinical studies, the dose to the heart
was not taken into account in these clinical studies. We therefore
propose that retrospective studies be initially performed to com-
pare radiation-toxicity in patients who were or were not receiving
ACE inhibitors during their radiation treatment where the heart
had been included in the radiation ﬁeld. This may probably show
an even greater protective effect of ACE inhibition when doses to
the heart are assessed. To further translate our ﬁndings to clinical
practice, clinical studies should be performed to investigate
whether ACE inhibition exerts the same protective effect on acute
radiation-induced heart damage and consequently on RILT as
shown in our preclinical study presented herein. Treatment with
ACE inhibitors should start directly after irradiation in order to pro-
tect against acute heart damage that potentially bears conse-
quences during the later stages of irradiation damage. Since the
occurrence of a subsequent cardiac event increases by 7.4% with
each gray of radiation to the heart [3], and patients treated for tho-
racic cancers still receive relevant doses to the heart, it is therefore
of great clinical importance to ﬁnd strategies to reduce this toxic-
ity. Interestingly, ACE inhibitors have been found to not change the
radiosensitivity of lung tumor cell lines [46] and even reduce the
risk of colorectal cancer [47].
To conclude, ACE inhibition reduces RILT by ameliorating acute
cardiac damage. ACE inhibition such aswith the clinically-approved
agent, captopril, may be a promising strategy to reduce early cardio-
pulmonary complications induced by radiotherapy to the thoracic
area in patients receiving a considerable dose to the heart.
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